Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex H Chang

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|February 23, 2026
Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort studyYuelu Guo, Lixia Ma, Fan Yang, et al.
Cytotherapy|December 10, 2022
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapyLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Frontiers in Oncology|July 19, 2021
Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHLYuan Meng, Biping Deng, Luan Rong, et al.
Cell Transplantation|September 5, 2023
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell LymphomaXueer Xu, Cheng Zu, Mingming Zhang, et al.
Frontiers in Immunology|June 19, 2026
Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphomaRui Liu, Zhonghua Fu, Fan Yang, et al.
Bone Marrow Transplantation|March 31, 2023
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapyShan Fu, Qiqi Zhang, Ruirui Jing, et al.
Frontiers in Immunology|May 22, 2023
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myelomaQiqi Zhang, Cheng Zu, Ruirui Jing, et al.
Cancer Immunology Research|July 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy StudyGuoqing Wei, Yanlei Zhang, Houli Zhao, et al.
Experimental Hematology & Oncology|January 3, 2025
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemiaTingting Yang, Yetian Dong, Mingming Zhang, et al.
HLA|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical StudyHaiqiong Zheng, Houli Zhao, Xinyi Zhu, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|February 23, 2026
Efficacy of BCMA CAR-T cell therapy and subsequent strategies in refractory and relapsed plasma cell leukemia: a retrospective cohort studyYuelu Guo, Lixia Ma, Fan Yang, et al.
Cytotherapy|December 10, 2022
Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapyLinqin Wang, Ruimin Hong, Linghui Zhou, et al.
Frontiers in Oncology|July 19, 2021
Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHLYuan Meng, Biping Deng, Luan Rong, et al.
Cell Transplantation|September 5, 2023
HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell LymphomaXueer Xu, Cheng Zu, Mingming Zhang, et al.
Frontiers in Immunology|June 19, 2026
Impact of <i>TP53</i> mutations on survival outcomes in the CAR-T era of large B-cell lymphomaRui Liu, Zhonghua Fu, Fan Yang, et al.
Bone Marrow Transplantation|March 31, 2023
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapyShan Fu, Qiqi Zhang, Ruirui Jing, et al.
Frontiers in Immunology|May 22, 2023
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myelomaQiqi Zhang, Cheng Zu, Ruirui Jing, et al.
Cancer Immunology Research|July 22, 2021
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy StudyGuoqing Wei, Yanlei Zhang, Houli Zhao, et al.
Experimental Hematology & Oncology|January 3, 2025
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemiaTingting Yang, Yetian Dong, Mingming Zhang, et al.
HLA|May 15, 2026
CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical StudyHaiqiong Zheng, Houli Zhao, Xinyi Zhu, et al.
Pageof 8